PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

about

A novel dysregulated pathway-identification analysis based on global influence of within-pathway effects and crosstalk between pathways.Pleiotropic effects of glitazones: a double edge sword?

P2860

Q34775286-3091DF63-5341-4E83-A341-E6BBF3865864 Q35025858-F25C61BF-729F-40E9-A03A-DFD1CC857D75

P2860

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

Item

http://www.wikidata.org/entity/Q36772391

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@ast

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@en

type

Item

label

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@ast

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@en

prefLabel

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@ast

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@en

P1476

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

@en

P2093

Ancha Baranova

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors

Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells

The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling.

PPAR delta: a dagger in the heart of the metabolic syndrome.

Breast cancer chemoprevention: beyond tamoxifen

The changing global patterns of female breast cancer incidence and mortality

Premenopausal fat intake and risk of breast cancer

The organization, promoter analysis, and expression of the human PPARgamma gene

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

P304

230893

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2008/230893

http://www.w3.org/2001/XMLSchema#string

P478

2008

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51419502

http://www.w3.org/2001/XMLSchema#string

P698

18645617

http://www.w3.org/2001/XMLSchema#string

P932

2467456

http://www.w3.org/2001/XMLSchema#string

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

about

P2860

P2860

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932